Advances in diagnostics could improve clinical management of a range of diseases in the healthcare system. Rapid infectious disease tests are critical for early disease detection for improving global health. Hence, the rise in cardiovascular and lifestyle diseases is expected to affect the market positively. Moreover, the prevalence of cardiovascular diseases is increasing due to lifestyle changes and an increase in diabetes, hypertension, obesity/overweight among young and elderly groups. An estimated 17.9 million deaths take place annually due to CVDs. Cardiovascular diseases (CVDs) are a major cause of death across the globe. The prevalence of chronic cardiovascular and metabolic diseases is increasing across the globe. The rapid cardiometabolic testing segment constituted a share of over 11% of the global market. Implantable sensor devices for continuous glucose monitoring that last three to seven days have been approved by the FDA and allow for strict glycemic controls with less discomfort for the patient. New technology is constantly being introduced. POCT glucose devices deliver rapid and relatively precise glucose measurements performed on the blood at patients’ bedsides, thereby offering quick results. Point of care testing (POCT) for glucose levels is a common procedure performed several times a day in different medical settings worldwide. In 2019, the blood glucose testing segment accounted for over 61% of the rapid diagnostics market. This research report includes a detailed segmentation by GLOBAL RAPID DIAGNOSTICS MARKET SEGMENTATION North America is expected to observe an incremental growth of over $6 billion by 2025 because of the eruption of several contagious diseases, such as COVID-19.The at-home testing segment is projected to observe a revenue of close to $23 billion by 2025 because of the increased preference for home-based healthcare services convenient and cost-effective.The blood glucose testing segment is likely to reach over $26 billion by 2025 due to the high prevalence of diabetics and other comorbidities.The consumables segment is expected to grow at the highest CAGR during the forecast period because of the growing usage of rapid tests in several POC sites.These simple test kits are based either on the detection of proteins from the COVID-19 virus in respiratory samples (e.g., sputum, throat swab) or the detection in blood or serum of human antibodies generated in response to the infection.
In response to the growing COVID-19 pandemic and the shortage of laboratory-based molecular testing capacity and reagents, multiple diagnostic test manufacturers have developed and begun selling rapid and easy-to-use devices to facilitate testing outside of laboratory settings. The pandemic, which was initially identified in Wuhan, Hubei Province, China, in December 2019, infected over 35.7 million people, resulting in approximately 1.05 million deaths across the globe till the end of September 2020. The segment has experienced unprecedented growth after the outbreak of the novel coronavirus. The global rapid diagnostics market is one of the major segments of the global in-vitro diagnostics market. The global rapid diagnostics market size to cross USD 43 billion by 2025, growing at a CAGR of 10% during 2020-2025.
0 kommentar(er)
